Vir Biotechnology, Inc. Form 8-K (Feb. 24, 2022)

Summary

Form 8-K for an event dated February 24, 2022, filed by Vir Biotechnology, Inc. Under Item 2.02, Results of Operations and Financial Condition, the report states that on February 24, 2022, the company issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2021, furnished as Exhibit 99.1. Under Item 7.01, Regulation FD Disclosure, the company posted an updated corporate presentation on February 24, 2022, furnished as Exhibit 99.2. Howard Horn, Chief Financial Officer and Secretary, signed with the date February 24, 2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 24, 2022

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39083 | 81-2730369
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
499 Illinois Street , Suite 500 San Francisco , California | 94158
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (415) 906-4324

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value | VIR | NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 | Results of Operations and Financial Condition.

On February 24, 2022, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2021. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.

Item 7.01 | Regulation FD Disclosure.

On February 24, 2022, the Company posted an updated corporate presentation under the “Investors” section of the Company’s website. The Company may use the corporate presentation from time to time in conversation with analysts, investors and others. A copy of the corporate presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Item 7.01, including the attached Exhibit 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act.

Item 9.01 | Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. | Description
99.1 | Press Release of the Company, dated February 24, 2022
99.2 | Corporate Presentation of the Company, dated February 24, 2022
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VIR BIOTECHNOLOGY, INC.
Date: February 24, 2022 | By: | /s/ Howard Horn
Howard Horn
Chief Financial Officer and Secretary

File and source

File

SEC_VIR_8-K_filed2022-02-24_0001193125-22-052116.htm

Size

28,238 bytes

SHA-256

f802011863b964009ecd19e3880f3850d722172dd1dc0f15c194d6badb0111a8

Our copy

SEC_VIR_8-K_filed2022-02-24_0001193125-22-052116.htm

Original

www.sec.gov